Human Brain Project Reviewed

After weathering serious criticism last year, the European Commission–backed effort to map the brain’s neural connections must reform or die, a review panel says.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The axonal nerve fibers of the brainWIKIMEDIA, CFCFIt’s been a rough nine months for the European Commission’s Human Brain Project (HBP). More than 250 of Europe’s top neuroscientists threatened to boycott the $1.6 billion effort to create a computer simulation of the human brain last July, and now a European Commission (EC) review panel has echoed some of the same concerns voiced by those scientists. In short, the HBP needs to change governance and improve the way that groups involved in the project collaborate and communicate, the panel said in a review issued last week (March 3). “The reviewers recommend that changes are made to ensure that the decision making processes are simple, fair, and transparent,” the document read. “It is important for the HBP to better articulate its strategic goals and to communicate them in a clear and realistic way, within the HBP, to the wider scientific community and to the public, and to avoid at all costs creating unrealistic expectations.”

Although the review doesn’t directly reference the grievances made public by a large group of European neuroscientists last year, it seems to echo their concerns. “We are very pleased, because [the review is] confirming the problems that we have been pointing out,” computational neuroscientist Alexandre Pouget of the University of Geneva in Switzerland, an HBP critic, told ScienceInsider. “They are making the exact same points we have made.”

In addition to suggesting a shake-up in the governance of the HBP, the reviewers also recommended enhanced collaboration among subprojects. The panel has given the HBP until June to implement the improvements.

The HBP’s chairman of the board of directors, Philippe Gillet, told ScienceInsider that he doesn’t view the assessment as entirely negative. “We are ranked as ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies